Previous close | 203.07 |
Open | 204.76 |
Bid | 208.13 x 1200 |
Ask | 208.32 x 800 |
Day's range | 204.30 - 210.63 |
52-week range | 179.59 - 234.09 |
Volume | |
Avg. volume | 744,403 |
Market cap | 17.454B |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | 47.92 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (1.42%) |
Ex-dividend date | 28 May 2024 |
1y target est | N/A |
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (GFAP), a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological injuries.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 12, 2024, to stockholders of record as of the close of business on May 28, 2024.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Mpox PCR Test Home Collection Kit to aid in the diagnosis of infection with non-variola Orthopoxvirus, including the monkeypox virus that causes monkeypox, also known as mpox. The test is the first mpox at-home collection kit authorized by FDA and is available to physicians to order for patients